An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

Key facts

Sponsor

Bristol-Myers Squibb

Principal Investigator

Bristol Myers Squibb

Bristol-Myers Squibb

Intervention

Nivolumab(drug)

Enrollment

743 enrolled

Eligibility

18 years · All sexes

Timeline

2015 – 2024

Study locations (30)

• Local Institution - 0066, Birmingham, Alabama, United States
• Local Institution - 0020, Los Angeles, California, United States
• Local Institution - 0015, San Francisco, California, United States
• Local Institution - 0084, San Francisco, California, United States
• Local Institution - 0061, Chicago, Illinois, United States
• Ochsner Clinic Foundation, New Orleans, Louisiana, United States
• Local Institution - 0083, New York, New York, United States
• Local Institution - 0093, New York, New York, United States
• Local Institution - 0016, Charlotte, North Carolina, United States
• Local Institution - 0095, Philadelphia, Pennsylvania, United States
• Local Institution - 0019, Philadelphia, Pennsylvania, United States
• UT Southwestern Medical Center, Dallas, Texas, United States
• Local Institution - 0017, San Antonio, Texas, United States
• Scott & White Memorial Hospital And Clinic, Temple, Texas, United States
• Local Institution - 0026, Seattle, Washington, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

Ono Pharmaceutical Co. Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07441369
  Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
  Fudan University
• RECRUITINGPHASE2NCT07175441
  Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
  Riboscience, LLC.
• RECRUITINGPHASE2NCT07560488
  Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE1, PHASE2NCT07291076
  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
  Bristol-Myers Squibb
• RECRUITINGPHASE2NCT07010497
  A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
  Asan Medical Center
• RECRUITINGPHASE1, PHASE2NCT07500220
  Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
  Beijing Biotech
• RECRUITINGPHASE2NCT07413354
  Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
  Tongji Hospital
• RECRUITINGNANCT07365527
  Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases
  Zealand University Hospital

See all trials for Adult hepatocellular carcinoma →